Latest Aura Biosciences News & Updates

See the latest news and media coverage for Aura Biosciences. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Aura Biosciences

Biotechnology company developing targeted therapies for solid tumors

aurabiosciences.com
Headquarters
Boston, United States
Founded year
2009
Company type
Public company
Number of employees
125–200

Last updated

Latest news about Aura Biosciences

In short: Aura Biosciences raised $299 million in a public offering and appointed Natalie Holles as CEO while advancing its Phase 3 clinical trial programs.

Company announcements

  • Aura Biosciences

    Aura Biosciences announces closing of $299 million public offering

    The offering includes full exercise of underwriters' option, selling 46 million shares and pre-funded warrants at $6.00 per share.

  • Aura Biosciences

    Aura Biosciences announces $260 million public offering pricing

    The offering includes 39,591,000 common stock shares at $6.00 each and pre-funded warrants. Proceeds will fund clinical programs and repurchase shares from Matrix Capital. Expected to close May 5, 2026.

  • Aura Biosciences

    Aura Biosciences announces proposed public offering

    It is offering common stock and pre-funded warrants; underwriters have a 30-day option to purchase up to 15% additional shares.

  • Aura Biosciences

    Aura Biosciences appoints Natalie Holles as CEO

    She succeeds founder Elisabet de los Pinos. Phase 3 CoMpass trial nears enrollment completion with 86 patients enrolled.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Aura Biosciences

Track Aura Biosciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Aura Biosciences competitors & trending companies

Browse news for competitors to Aura Biosciences and other trending companies.